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ORIGINAL ARTICLE
The use of morphine in intravenous patient-
controlled analgesia (PCA) is frequently associated
with side effects such as nausea and vomiting.
Various agents, such as butyrophenones,1 phe-
nothiazines,2 antihistamines,3 and nonsteroidal
anti-inflammatory drugs4 have been added to
opioids to reduce postoperative PCA-related side
effects. In a 1997 study, Gan et al revealed that
low-dose infusion of naloxone with PCA morphine
not only decreased opioid side effects but also
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Background/Purpose: Admixing an ultralow dose of naloxone with intravenous morphine patient-controlled
analgesia (PCA) has been shown to decrease postoperative nausea. However, the cut-off ratio of the naloxone-
morphine admixture for antiemetic effects has not been investigated. The purpose of this study was to inves-
tigate the cut-off ratio of naloxone-morphine admixture in PCA for antiemesis after gynecologic surgery.
Methods: This double-blind study enrolled 120 female patients who were scheduled for gynecologic surgery
under general anesthesia. Patients were randomly allocated to one of three groups (n = 40 for each group).
The concentration of naloxone and morphine respectively was 0 μg/mL and 1 mg/mL in group 1, 0.1 μg/mL
and 1 mg/mL in group 2 (1:10,000), and 1μg/mL and 1 mg/mL in group 3 (1:1000). Morphine consumption,
verbal rating score of wound pain at rest and with exertion, and morphine-related side effects were investigated
at 1, 2, 4 and 24 hours postoperatively.
Results: A total of 112 patients completed the study (37 in group 1, 36 in group 2, 39 in group 3). The in-
cidence of nausea during the postoperative 4–24 hours was significantly lower in group 3 than in group 1
(23.1% vs. 56.8%, p < 0.05). Furthermore, the overall incidence of severe nausea was significantly lower in
group 3 than in group 1 (2.6% vs. 24.3%, p < 0.05) as was the rescue antiemetic requirements (5.1% vs.
24.3%, p < 0.05). However, there were no significant differences between groups 2 and 1. The pain scores
(at rest and with exertion) and 24-hour morphine consumption were not significantly different among
the three groups.
Conclusion: The antiemetic efficacy of ultralow-dose naloxone combined with PCA morphine is limited
by a cut-off ratio of naloxone to morphine of 1:10,000. [J Formos Med Assoc 2008;107(6):478–484]
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improved analgesia.5 Clinically, it is not convenient
to use an infusion pump with a PCA machine.
Therefore, combination of low-dose naloxone and
morphine in intravenous postoperative PCA has
been investigated as a more convenient method.
The results of naloxone-morphine combinations
were initially disappointing. Sartain et al found
that combining naloxone (26.7 μg/mL) and mor-
phine (2 mg/mL) did not have any benefit.6
Cepeda et al found that addition of low-dose
naloxone (6μg/mL) with morphine (1mg/mL) did
not decrease the incidence of opioid side effects.7
In a later study, Cepeda et al8 found that addi-
tion of ultralow-dose naloxone (0.6 μg/mL) with
morphine (1 mg/mL) did not affect analgesia and
the opioid requirement but decreased the inci-
dence of opioid side effects. However, no study
has investigated the antiemetic effects of lower
ratios of the naloxone-morphine admixture. The
purpose of this study was to investigate the cut-
off ratio of the naloxone-morphine admixture in
PCA for antiemesis after gynecologic surgery.
Materials and Methods
Patients
This randomized, double-blind, placebo-con-
trolled study was approved by the Hospital
Committee for Human Investigation. Written in-
formed consent was obtained from all patients.
A total of 120 Taiwanese women (18–66 years,
ASA physical status of I or II) scheduled for elec-
tive total abdominal hysterectomy under general
anesthesia and postoperative analgesia with a PCA
device were assessed for inclusion in the study.
Patients with known morphine allergy or who re-
ceived opioids or any antiemetics within 7 days
of the study were excluded.
Randomization and blinding
A specially trained nurse anesthetist, not involved
in any subsequent assessments, was in charge of
the study medication preparation and group as-
signment. According to a computer-generated ran-
dom number table, patients were allocated to one
of three groups (n = 40 per group). The control
group (group 1) received morphine 1 mg/mL
alone. The two treatment groups each received a
naloxone-morphine admixture with a ratio of
naloxone to morphine of 1:10,000 or 1:1,000
(groups 2 and 3, respectively). The study solutions
were diluted in saline to produce equal volumes
to ensure proper blinding. The two naloxone-
morphine admixtures were prepared by mixing
0.01 and 0.1 mg of naloxone (groups 2 and 3, re-
spectively) with 100 mg of morphine in 0.9%
saline to a total volume of 100 mL. The study was
double-blinded, with the patient, the patient’s fam-
ily, anesthesiologist, nursing staff, and evaluators
all unaware of the randomization.
Rationale for the naloxone-morphine
admixture ratios
The rationale for the concentration of naloxone
in group 3 was based on the average amount of
morphine required in our previous study in a sim-
ilar population.3 We estimated that if we used a
ratio of naloxone to morphine of 1:1000, the dose
of naloxone a patient would receive would be
approximately 0.065 μg/kg/hr in the first 4 hours
when the PCA requirements are the highest, and
0.012 μg/kg/hr afterwards. These naloxone doses
are similar to the ultralow doses that have been re-
ported to augment opioid effects in animal mod-
els,9,10 and are very close to the ultralow doses of
naloxone that have been proven to be effective in
reducing opioid side effects while preserving the
adequacy of pain management.8 Moreover, 10%
of this ratio was chosen for group 2 (1:10,000) 
to disclose whether a minimal naloxone concen-
tration would still be potent enough to reduce
morphine-induced emesis.
Anesthesia
Before the surgery, all patients were instructed on
the operational use of the PCA system and a 0–10
visual analog scale (VAS), where 0 represented
no pain and 10 the worst pain imaginable. All
patients fasted at least 8 hours before surgery. 
A standard general anesthetic was given, compris-
ing thiopental 3–5 mg/kg, fentanyl 1.5–3 μg/kg,
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and atracurium 0.5–0.8 mg/kg. Anesthesia was
maintained by isoflurane 0.8–1.5% in oxygen.
The last dose of fentanyl had to be given 30 
minutes prior to the end of the surgical proce-
dure. Edrophonium 0.5–1 mg/kg and atropine
0.015 mg/kg were given to antagonize residual
neuromuscular block at the end of surgery.
Postoperative management
Postoperative analgesia was provided in the re-
covery room immediately after the patient com-
plained of pain. At the discretion of the nursing
staff or the attending anesthesiologist, the assigned
PCA solution in 1- to 2-mL increments was ad-
ministered to the patient until the patient was
comfortable. When the patient was stable and
sufficiently alert, PCA was initiated. One milliliter
of PCA solution was administered on demand
with a 5-minute lockout and no background in-
fusion was set. Patients were continuously moni-
tored with a three-lead electrocardiogram, digital
pulse oximetry, and noninvasive blood pressure
monitoring during their stay in the postoperative
recovery room. After a 1-hour stay in the recovery
room, patients were transferred to wards when
their vital signs were stable.
Postoperative evaluation
Data obtained for each patient included age,
weight, height, and duration of anesthesia.
Assessments of pain, nausea, vomiting, pruritus,
sedation, PCA morphine and rescue antiemetic
and antipruritic requirements, as well as any noted
side effects, were recorded by an independent
clinical investigator at 1, 2, 4 and 24 hours post-
operatively. Patients were instructed to report the
intensity of pain at rest and with exertion (cough-
ing and deep inspiration) using VAS and to use
PCA to maintain a VAS ≤ 3. We asked patients to
categorize the severity of nausea, vomiting and
pruritus at the end of the study period as none,
mild, moderate or severe. Nausea and vomiting
was treated with intravenous prochlorperazine
10 mg; pruritus was treated with intravenous
diphenhydramine 30 mg. The symptomatic treat-
ments were repeated if necessary. The level of 
sedation was assessed by the investigator by using
a 5-point scale (0 = fully awake; 1 = drowsy, closed
eyes; 2 = asleep, easily aroused with light tactile
stimulation or a simple verbal command; 3 =
asleep, arousable only by strong physical stimu-
lation; 4 = unarousable).11 A sedation score ≥ 3
was regarded as unacceptable in this context and
was to be assessed and reported by any healthcare
personnel with the subject then being switched
to an alternate analgesic modality. If respiratory
depression occurred (respiratory rate < 8 breaths/
min; SaO2 < 90%; sedation score ≥ 3), PCA was
turned off and the patient given naloxone 40 μg
intravenously. Urinary retention could not be 
assessed due to the routine use of indwelling
catheters in all patients.
Statistical analysis
A series of one-way analyses of variance was con-
ducted to examine differences among the three
groups with respect to continuous variables. If a
significant difference was found, Tukey’s post hoc
comparisons were used to detect the intergroup
differences. The Kruskal-Wallis test was used to de-
termine differences among the three groups with
respect to ordinal variables, and post hoc compar-
isons between groups were made using the Mann-
Whitney U test. Categorical variables were analyzed
using 2 × 2 χ2 tests to determine the differences
between group 1 and group 2 and the differences
between group 1 and group 3. All follow-up ana-
lyses were corrected for the number of simulta-
neous contrasts by using Bonferroni’s adjustments.
A p value < 0.05 was considered statistically 
significant.
Results
A total of 120 patients were enrolled in the study
over an 8-month period. Eight patients were sub-
sequently excluded for a variety of reasons: one
patient experienced a suspected antibiotic allergy
during surgery; two patients were re-operated on
within 24 hours of surgery for continuous hemor-
rhage; two patients had the PCA machine replaced
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twice because of pump malfunction; and data col-
lection was incomplete in three patients. Thus, 112
patients completed the study: 37 in group 1; 36 in
group 2; and 39 in group 3. Patient demographic
and intraoperative variables were comparable in
all groups (Table 1).
Pain intensities at rest and with exertion at
each of the observatory time points did not differ
statistically among the groups (Figures 1 and 2),
nor did morphine consumption (Figure 3). In the
first 4 postoperative hours, when the morphine
requirements were highest, patients in groups 2
and 3 respectively received average doses of nalox-
one that were 0.006 and 0.061 μg/kg/hr (taking
the average patient’s weight in the corresponding
group), and then 0.001 and 0.008 μg/kg/hr after-
wards for the following 4–24 hours. There was no
report of inadequate analgesia, morphine-related
respiratory depression or somnolence (sedation
score ≥ 3).
The incidence and severity of nausea, vomiting,
pruritus, and requests for rescue antiemetic and
antipruritic medications are reported in Table 2.
Compared with the control group, the overall
(0–24 hour) incidence of nausea and vomiting
was not significantly reduced in group 3. How-
ever, the incidence of nausea during the postop-
erative 4–24 hours was significantly lower in group
3 than in group 1 (23.1% vs. 56.8%, p < 0.05).
Furthermore, the overall incidence of severe nau-
sea was significantly lower in group 3 than in
group 1 (2.6% vs. 24.3%, p < 0.05). The incidence
of severe vomiting was also lower in group 3 than
in group 1 (2.6% vs. 18.9%, p = 0.054); however,
the difference was not statistically significant.
The number of patients requiring prochlorper-
azine was also significantly less in group 3 than
in group 1 (5.1% vs. 24.3%, p < 0.05). Addition-
ally, the total number of doses of prochlorper-
azine was least in group 3. In contrast, there were
no significant differences between group 2 and
group 1 with regard to the incidence and severity
of nausea and vomiting, and to the antiemetic
requirements.
Figure 1. Visual analog scale (VAS) at rest (mean and 95%
confidence intervals). There were no significant differences
among groups. Group 1= control group; Group 2=1:10,000
naloxone-morphine admixture group; Group 3 = 1:1000
naloxone-morphine admixture group.
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Table 1. Patient demographic and intraoperative data*†
Group 1 (n = 37) Group 2 (n = 36) Group 3 (n = 39)
Age (yr) 44.8 (21–62) 44.5 (23–66) 45.7 (23–65)
ASA (I/II) 20/17 21/15 19/20
Height (cm) 157.0 ± 5.8 155.7 ± 4.8 156.1 ± 5.6
Weight (kg) 56.2 ± 8.2 56.8 ± 9.6 58.9 ± 9.8
Duration of anesthesia (min) 113 ± 42 125 ± 46 119 ± 39
Intraoperative fentanyl used (μg) 130.2 ± 36.7 129.1 ± 34.1 131.2 ± 38.1
*Data presented as mean (range), n or mean± standard deviation; †the three groups were similar for all variables tested. Group 1 = control
group; Group 2 = 1:10,000 naloxone-morphine admixture group; Group 3 = 1:1000 naloxone-morphine admixture group.
Figure 2. Visual analog scale (VAS) with exertion (mean
and 95% confidence intervals). There were no significant
differences among groups. Group 1 = control group; Group
2 = 1:10,000 naloxone-morphine admixture group; Group
3 = 1:1000 naloxone-morphine admixture group.
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The incidence and severity of pruritus were
similar among the groups. Most patients expe-
riencing pruritus reported pruritus as mild in
severity. Two patients, one each from group 1
and 3, reported moderate pruritus and required
diphenhydramine.
Discussion
This study shows that the addition of naloxone
to PCA morphine at a naloxone-to-morphine ratio
of 1:1000 significantly reduces morphine-induced
nausea and the need for further antiemetic treat-
ment without affecting analgesia. A ratio of nalox-
one to morphine of 1:10,000 does not decrease the
opioid side effects. The concentration-dependent
efficacy demonstrates that the ratio of naloxone-
morphine admixtures plays a critical role in the
prophylaxis of PCA morphine-induced emesis.
The use of opioid antagonists to decrease opi-
oid side effects while preserving opioid analgesia
is an attractive concept. As opioid side effects and
analgesia have different dose-response curves5
and opioid side effects are attributable to activa-
tion of inhibitory mu opioid receptors (e.g. on
interneurons),5,12,13 the administration of small
doses of opioid antagonists may be potentially
Table 2. Main adverse effects and rescue antiemetic and antipruritic requirements*
Group 1 (n = 37) Group 2 (n = 36) Group 3 (n = 39)
Nausea
0–24 hr 26 (70.3) 25 (69.4) 19 (48.7)
Mild 8 8 12
Moderate 9 10 6
Severe 9 (24.3) 7 (19.4) 1 (2.6)†
0–4 hr 17 (45.9) 20 (55.6) 16 (41)
4–24 hr 21 (56.8) 17 (47.2) 9 (23.1)†
Vomiting
0–24 hr 16 (43.2) 14 (38.9) 13 (33.3)
Mild 3 2 7
Moderate 6 6 5
Severe 7 (18.9) 6 (16.7) 1 (2.6)
0–4 hr 7 (18.9) 10 (27.8) 6 (15.4)
4–24 hr 13 (35.1) 10 (27.8) 7 (17.9)
Patients requiring prochlorperazine 9 (24.3) 8 (22.2) 2 (5.1)†
Total no. of doses 14 10 3
Pruritus 7 (18.9) 5 (13.9) 2 (5.1)
Patients requiring diphenhydramine 1 0 1
Sedation score ≥ 3 0 0 0
Respiratory depression 0 0 0
*Data presented as n (%) or n; †p<0.05, group 3 vs. group 1. Group 1 = control group; Group 2 = 1:10,000 naloxone-morphine admixture
group; Group 3 = 1:1000 naloxone-morphine admixture group.
Figure 3. Morphine consumption (mean and 95% confi-
dence intervals). There were no significant differences among
groups. Group 1 = control group; Group 2 = 1:10,000
naloxone-morphine admixture group; Group 3 = 1:1000
naloxone-morphine admixture group.
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beneficial to obtain this goal. Depending on the
methods of administration (separate continuous
infusion vs. mixed intermittent bolus) and the
drug doses (low vs. ultralow) applied, the use of
naloxone with intravenous PCA morphine was
found to result in either beneficial,5,8,14 adverse7
or no effects.6
Although the success of naloxone in prevent-
ing morphine-induced side effects is consistently
reported for studies in which naloxone was ad-
ministered by continuous infusion,5,14 a separate
infusion is seen as inconvenient in clinical practice.
Cepeda et al were the first to assess the applica-
bility of adding naloxone to a morphine solution
for PCA in male and female patients undergoing
a range of surgical procedures.7 No benefit in
terms of opioid side effects was seen, and in fact,
the study was not designed to detect this benefit.
Whether or not adding naloxone decreases side
effects, the naloxone-to-morphine ratio of 6:1000
in the study was not a helpful option because it
reversed the analgesia. The lack of benefit from
naloxone was similarly reported in the study by
Sartain et al, in which a naloxone-to-morphine
ratio of 13.3:1000 was employed for postopera-
tive PCA in women undergoing hysterectomy.6
Although they did not find naloxone at risk of
reversing analgesia with this higher dose, neither
could they find any antiemetic benefit from nal-
oxone. The lack of a constant concentration of nal-
oxone from intermittent administration by PCA
has been suggested to be the reason why naloxone
was ineffective in preventing morphine-induced
side effects.6,14
In view of the analgesia reversal observed
with the 6:1000 naloxone-morphine admixture,7
Cepeda et al subsequently used a lower ratio
(6:10,000) in their recent study8 to investigate if
the opioid analgesia enhancement of ultralow
doses of naloxone in animal models9,10,15 was also
present in humans. With this ratio, they found
that ultralow-dose naloxone did not affect anal-
gesia or morphine requirements, but it decreased
the incidence of nausea and pruritus during the
24-hour postoperative period.8 Using methods
similar to Cepeda et al, we combined two ultralow
doses of naloxone with PCA morphine. With a
naloxone-to-morphine ratio of 1:1000 in group 3,
a decrease in nausea was observed during the
postoperative 4–24 hours. Reductions in both the
severity of nausea and request for rescue antieme-
sis were also evident. In accordance with the
findings of Cepeda et al, we did not observe the
paradoxical effect of naloxone enhancement of
opioid analgesia nor the undesired effect of anal-
gesia reversal. In the first 4 hours postoperatively,
when the morphine requirements were highest,
patients in group 3 received an average dose of nal-
oxone of 0.06 μg/kg/hr, and then 0.008 μg/kg/hr
in the following 4–24 hours. Similarly, these nal-
oxone doses were very close to the doses of nalox-
one (0.009–0.05 μg/kg/hr) used in the recent
Cepeda et al study.8 In contrast, the antinausea
benefits of naloxone were no longer demonstra-
ble at the lower ratio of 1:10,000 in group 2. While
the naloxone doses in group 2 (0.001–0.006 μg/
kg/hr), as those in group 3, also mirrored the 
ultralow doses that have been reported to augment
opioid effects in mice (0.001–0.1 μg/kg),9,10,15
neither analgesic enhancement nor an antiemetic
effect was evident in our study at this dose. We
believe that patients in group 2 received less than
an effective dose of naloxone to prevent nausea.
The antinausea efficacy of naloxone in group
3 was apparent during the 4–24 hours postoper-
atively. The incidence of nausea in the first 4 hours
was generally high among the groups. More than
65–84% of the patients experiencing nausea dur-
ing the 24 hours postoperatively reported nausea
within the first 4 hours. The lack of antiemetic ben-
efits from naloxone in the first 4 hours was likely
to be due to a combination of residual anesthetic
effects in the immediate postoperative period, the
nature of the surgical procedures, and patients
being at high risk of postoperative nausea (e.g.
women undergoing abdominal hysterectomy).
As multiple antiemetic combinations for postop-
erative nausea and vomiting prophylaxis have
shown promising results,16,17 other antiemetics
may be employed as comedication drugs in com-
bination with ultralow doses of naloxone to exert
a more powerful effect against PCA opioid-induced
Naloxone-morphine admixture in PCA
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emesis. In terms of antipruritic efficacy, naloxone
has been shown to be effective against PCA opioid-
induced pruritus.8,14 In our study, the overall in-
cidence of pruritus was higher in group 1 than in
group 3 (18.9 vs. 5.1%, p = 0.16). However, our
sample size was too small to detect a statistical
difference in the incidence of pruritus.
Another concern with the use of the naloxone-
morphine admixture is the potential incompati-
bility of this combination. Although chemical
compatibility data between naloxone and mor-
phine are lacking, in two published studies, nal-
oxone was shown to have clinical activity when
similarly combined with morphine.8,18
In conclusion, addition of an ultralow dose
of naloxone to PCA morphine at a naloxone-to-
morphine ratio of 1:1000, but not 1:10,000, sig-
nificantly reduced morphine-induced nausea and
the need for further antiemetic treatment without
affecting analgesia. The antiemetic efficacy of ul-
tralow-dose naloxone combined with PCA mor-
phine is therefore limited by a cut-off ratio of
naloxone to morphine of 1:10,000. However, the
optimal ratio of naloxone-morphine admixture
for the prophylaxis of PCA morphine-induced
side effects still needs to be evaluated in future
studies.
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